- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Relapsed or refractory multiple myeloma (RRMM)
- Meeting Date: March 2026
- Public Summary Document (PSD) March 2026 PBAC Meeting - (PDF)
- Public Summary Document (PSD) March 2026 PBAC Meeting - (DOCX)
Teclistamab – March 2026
Solution for subcutaneous injection 30 mg in 3 mL, Solution for subcutaneous injection 153 mg in 1.7 mL
Last updated
11 March 2026